Results of recent pre-clinical studies with AMF-1c-120 (Amorfix Life Sciences, Ltd) shows that this proprietary anti-ovarian cancer antibody, when administered to live animals, targets and binds to tumors in a very localized and concentrated manner. This is a significant finding because it shows that the antibody retains its tumor-specific binding in vivo.
As part of the pre-clinical study, cancer cells were…Continue
Added by Editorial Team on August 14, 2013 at 6:30am — No Comments
Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin (CMC-544) in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for intensive high-dose chemotherapy.
In this study, inotuzumab ozogamicin was administered on a once-a-month schedule in combination with rituximab…Continue
Added by Editorial Team on May 20, 2013 at 6:00pm — No Comments
On February 22nd, 2013, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla™, Genentech), as a single medicine, for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with trastuzumab (Herceptin®, Genentech) and a taxane chemotherapy. The newly approved drug is the…Continue
Added by Peter Hofland, PhD on February 23, 2013 at 5:00pm — No Comments
Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma (HL) patients were…Continue
Added by Peter Hofland, PhD on December 13, 2011 at 5:00pm — No Comments
Data reported today demonstrating that prolonged treatment with Brentuximab Vedotin (SGN-35; Adcetris™, Seattle Genetics) beyond 16 cycles of therapy was associated with clinically meaningful durations of response with a manageable safety profile. In addition, data were presented showing that Brentuximab Vedotin is a viable option for reducing tumor burden prior to allogeneic stem cell transplant. The data were presented at the…Continue
Added by Peter Hofland, PhD on December 12, 2011 at 2:30pm — No Comments
Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer , have entered into a collaboration in which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.…
Added by Peter Hofland, PhD on January 6, 2011 at 11:30am — No Comments
Added by Peter Hofland, PhD on October 8, 2010 at 12:00pm — No Comments